PTC Therapeutics, Inc.
PTCT
Rank in Stocks
#3385
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Share Price
$61.65
Last synced: 2026-10-19
Market Cap
$5.15B
Change (1 day)
4.07%
Change (1 year)
-9.82%
Country
US
Trade PTC Therapeutics, Inc. (PTCT)
Category
Healthcare
Number of shares outstanding for PTC Therapeutics, Inc. (PTCT)
Number of shares outstanding as of June 2026: 83.01M
According to PTC Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 83.01M. At the end of December 2023 the company had 74.84M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for PTC Therapeutics, Inc. (PTCT) from 2011 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 83.01M | 8.02% |
| 2024 | 76.85M | 2.68% |
| 2023 | 74.84M | 4.34% |
| 2022 | 71.73M | 1.79% |
| 2021 | 70.47M | 6.72% |
| 2020 | 66.03M | 12.17% |
| 2019 | 58.86M | 26.38% |
| 2018 | 46.58M | 19.09% |
| 2017 | 39.11M | 14.88% |
| 2016 | 34.04M | 1.27% |
| 2015 | 33.62M | 6.51% |
| 2014 | 31.57M | 146.13% |
| 2013 | 12.82M | -9.61% |
| 2012 | 14.19M | 0.00% |
| 2011 | 14.19M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 205.88% |
US
|
|
| 396.00M | 377.07% |
US
|
|
| 478.91M | 476.96% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -25.08% |
NL
|
